📊 CPHI Key Takeaways
Is China Pharma Holdings, Inc.. (CPHI) a Good Investment?
China Pharma faces a critical liquidity crisis with current ratio of 0.28x and only $168.5K cash against $114.6K annual free cash burn, implying ~18-month runway. Persistent operating losses at -113.6% margin with declining revenue and negative operating cash flow indicate an unsustainable business model at imminent risk of insolvency.
CHINA PHARMA HOLDINGS, INC. shows severely weak fundamentals, with sharply declining revenue, negative gross margin, and very large operating and net losses relative to sales. The balance sheet still has positive equity, but acute liquidity stress, minimal cash, and negative interest coverage materially increase financial risk and make the growth profile low quality.
China Pharma Holdings, Inc.. Key Strengths (CPHI)
- Gross margin of 29% demonstrates core products retain some commercial viability at product level
- Stockholders equity of $37M provides accounting buffer above total liabilities of $8.1M
- Net loss improved 32.7% year-over-year suggesting partial operational improvement trajectory
- Positive stockholders equity of $8.31M provides some residual balance-sheet support
- Debt/equity of 0.52x is not extreme relative to equity base
- Free cash flow loss is smaller than accounting losses, suggesting limited capital spending burden
CPHI Stock Risks: China Pharma Holdings, Inc.. Investment Risks
- Critical liquidity crisis: current ratio 0.28x and quick ratio 0.07x with only $168.5K cash position company at immediate solvency risk
- Negative free cash flow of -$114.6K annually against minimal cash creates ~18-month runway before potential insolvency without capital infusion
- Persistent deep operating losses at -113.6% margin with declining revenue (-8.5% YoY) and negative operating cash flow indicate broken business economics
- Pharmaceutical sector capital requirements incompatible with company's inability to achieve profitability or positive cash generation
- Revenue declined 35.4% YoY, indicating major deterioration in demand or commercial execution
- Negative gross, operating, and net margins show the core business is currently unprofitable before and after overhead
- Current ratio of 0.35x, quick ratio of 0.10x, and cash of only $267.62K point to serious near-term liquidity pressure
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway - absolute critical indicator of survival timeline
- Revenue stabilization and positive year-over-year growth - prerequisite for any path to viability
- Operating margin improvement trajectory toward breakeven and positive operating cash flow
- Revenue stabilization and return to positive gross margin
- Cash balance and current ratio improvement
China Pharma Holdings, Inc.. (CPHI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CPHI Profit Margin, ROE & Profitability Analysis
CPHI vs Healthcare Sector: How China Pharma Holdings, Inc.. Compares
How China Pharma Holdings, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is China Pharma Holdings, Inc.. Stock Overvalued? CPHI Valuation Analysis 2026
Based on fundamental analysis, China Pharma Holdings, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
China Pharma Holdings, Inc.. Balance Sheet: CPHI Debt, Cash & Liquidity
CPHI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: China Pharma Holdings, Inc..'s revenue has declined by 58% over the 5-year period, indicating business contraction. The most recent EPS of $-2.71 indicates the company is currently unprofitable.
CPHI Revenue Growth, EPS Growth & YoY Performance
CPHI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $983.5K | -$785.6K | $-0.04 |
| Q3 2025 | $756.2K | -$528.4K | $-0.17 |
| Q2 2025 | $924.9K | -$528.4K | $-0.16 |
| Q1 2025 | $1.1M | -$785.6K | $-0.24 |
| Q3 2024 | $1.1M | -$476.0K | $-0.06 |
| Q2 2024 | $924.9K | -$476.0K | $-0.09 |
| Q3 2023 | $1.8M | -$476.0K | $-0.06 |
| Q2 2023 | $1.1M | -$593.0K | $-0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
China Pharma Holdings, Inc.. Dividends, Buybacks & Capital Allocation
CPHI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for China Pharma Holdings, Inc.. (CIK: 0001106644)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CPHI
What is the AI rating for CPHI?
China Pharma Holdings, Inc.. (CPHI) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CPHI's key strengths?
Claude: Gross margin of 29% demonstrates core products retain some commercial viability at product level. Stockholders equity of $37M provides accounting buffer above total liabilities of $8.1M. ChatGPT: Positive stockholders equity of $8.31M provides some residual balance-sheet support. Debt/equity of 0.52x is not extreme relative to equity base.
What are the risks of investing in CPHI?
Claude: Critical liquidity crisis: current ratio 0.28x and quick ratio 0.07x with only $168.5K cash position company at immediate solvency risk. Negative free cash flow of -$114.6K annually against minimal cash creates ~18-month runway before potential insolvency without capital infusion. ChatGPT: Revenue declined 35.4% YoY, indicating major deterioration in demand or commercial execution. Negative gross, operating, and net margins show the core business is currently unprofitable before and after overhead.
What is CPHI's revenue and growth?
China Pharma Holdings, Inc.. reported revenue of $983.5K.
Does CPHI pay dividends?
China Pharma Holdings, Inc.. does not currently pay dividends.
Where can I find CPHI SEC filings?
Official SEC filings for China Pharma Holdings, Inc.. (CIK: 0001106644) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CPHI's EPS?
China Pharma Holdings, Inc.. has a diluted EPS of $-0.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CPHI's fundamental grade?
Based on our AI fundamental analysis in June 2026, China Pharma Holdings, Inc.. has a D grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CPHI stock overvalued or undervalued?
Valuation metrics for CPHI: ROE of -3.1% (sector avg: 15%), net margin of -116.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CPHI's AI grade for 2026?
Our dual AI analysis gives China Pharma Holdings, Inc.. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CPHI's free cash flow?
China Pharma Holdings, Inc..'s operating cash flow is $-55.3K, with capital expenditures of $59.3K. FCF margin is -11.7%.
How does CPHI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -116.2% (avg: 12%), ROE -3.1% (avg: 15%), current ratio 0.28 (avg: 2).